Home › Obesity
Pag-aaral pangklinika para sa Obesity na nagre-recruit sa U.S.
473 pag-aaral para sa Obesity ang nagre-recruit ng mga kalahok sa mga site sa buong Estados Unidos.
Mga lungsod na may pinakamaraming pag-aaral
- Houston, TX44 pag-aaral
- Chicago, IL40 pag-aaral
- New York City, NY39 pag-aaral
- San Antonio, TX39 pag-aaral
- Washington, DC34 pag-aaral
- Dallas, TX33 pag-aaral
- Orlando, FL33 pag-aaral
- Miami, FL28 pag-aaral
- Boston, MA26 pag-aaral
- Atlanta, GA26 pag-aaral
- Los Angeles, CA25 pag-aaral
- St. Louis, MO25 pag-aaral
- Jacksonville, FL25 pag-aaral
- San Diego, CA24 pag-aaral
- Baltimore, MD24 pag-aaral
- Birmingham, AL22 pag-aaral
- Austin, TX22 pag-aaral
- Philadelphia, PA22 pag-aaral
- Indianapolis, IN22 pag-aaral
- Las Vegas, NV21 pag-aaral
- Nashville, TN20 pag-aaral
- Aurora, CO20 pag-aaral
- Tucson, AZ20 pag-aaral
- Cincinnati, OH20 pag-aaral
- Phoenix, AZ19 pag-aaral
- Arlington, VA18 pag-aaral
- Durham, NC17 pag-aaral
- Louisville, KY17 pag-aaral
- Wilmington, NC17 pag-aaral
- Charlotte, NC16 pag-aaral
- Roswell, GA16 pag-aaral
- Concord, CA16 pag-aaral
- Salt Lake City, UT16 pag-aaral
- Havelock, NC15 pag-aaral
- Providence, RI14 pag-aaral
- Honolulu, HI14 pag-aaral
- Baton Rouge, LA14 pag-aaral
- Johns Creek, GA14 pag-aaral
- Rochester, NY14 pag-aaral
- Deltona, FL14 pag-aaral
Ayos sa estado
- Alabama38 pag-aaral
- Arizona40 pag-aaral
- Arkansas12 pag-aaral
- California99 pag-aaral
- Colorado25 pag-aaral
- Connecticut24 pag-aaral
- District of Columbia12 pag-aaral
- Florida80 pag-aaral
- Georgia46 pag-aaral
- Hawaii14 pag-aaral
- Idaho22 pag-aaral
- Illinois55 pag-aaral
- Indiana27 pag-aaral
- Iowa10 pag-aaral
- Kansas32 pag-aaral
- Kentucky30 pag-aaral
- Louisiana32 pag-aaral
- Maine3 pag-aaral
- Maryland52 pag-aaral
- Massachusetts42 pag-aaral
- Michigan31 pag-aaral
- Minnesota27 pag-aaral
- Mississippi15 pag-aaral
- Missouri55 pag-aaral
- Montana7 pag-aaral
- Nebraska9 pag-aaral
- Nevada23 pag-aaral
- New Hampshire3 pag-aaral
- New Jersey17 pag-aaral
- New Mexico8 pag-aaral
- New York73 pag-aaral
- North Carolina58 pag-aaral
- North Dakota8 pag-aaral
- Ohio43 pag-aaral
- Oklahoma20 pag-aaral
- Oregon17 pag-aaral
- Pennsylvania47 pag-aaral
- Rhode Island16 pag-aaral
- South Carolina41 pag-aaral
- South Dakota5 pag-aaral
- Tennessee38 pag-aaral
- Texas84 pag-aaral
- Utah25 pag-aaral
- Virginia43 pag-aaral
- Washington31 pag-aaral
- West Virginia4 pag-aaral
- Wisconsin11 pag-aaral
Mga pag-aaral na kamakailan lamang in-update
Opisyal na teksto ng pag-aaral (English)
Glucagon-Like Peptide-1 Receptor Agonists to Attenuate Metabolic Risk in Individuals With Duchenne Muscular Dystrophy
Nagre-recruitPhase 1/2
Edad 18 pataas · Kalalakihan · Na-update Nob 12, 2026 · NCT07642635Testing Just-in-Time Adaptive Interventions (JITAIs) to Prevent Goal Disengagement in Response to Weight Regain
Nagre-recruit
Edad 18 hanggang 75 · Lahat ng kasarian · Na-update Nob 10, 2026 · NCT07708064Efficacy and Safety of Olatorepatide Versus Placebo in Adults With Moderate to Severe Hidradenitis Suppurativa Living With Overweight or Obesity
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 10, 2026 · NCT07830329Family COMIDA (Consumo de Opciones Más Ideales De Alimentos) (Eating More Ideal Food Options)
Nagre-recruitMalugod na tinatanggap ang malusog na boluntaryo
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 10, 2026 · NCT07144800Semaglutide in Youth With Autism Spectrum Disorder
Nagre-recruitPhase 4
Edad 12 hanggang 18 · Lahat ng kasarian · Na-update Nob 9, 2026 · NCT07770152Home Self-administration of Maridebart Cafraglutide With Autoinjector in Adults Living With Obesity or Overweight
Nagre-recruitPhase 3
Edad 18 hanggang 99 · Lahat ng kasarian · Na-update Nob 9, 2026 · NCT07871409A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 9, 2026 · NCT07351045Adapting and Assessing the Feasibility of a Telehealth Diabetes Prevention Program for Hispanic Adolescents
Nagre-recruitMalugod na tinatanggap ang malusog na boluntaryoMay bayad para sa mga kalahok
Edad 14 hanggang 16 · Lahat ng kasarian · Na-update Nob 9, 2026 · NCT06943001PATHS-UP Health Behavior Self-monitoring Mobile App for Adolescents
Nagre-recruitMalugod na tinatanggap ang malusog na boluntaryo
Edad 12 hanggang 18 · Lahat ng kasarian · Na-update Nob 9, 2026 · NCT06959901A Study to Evaluate Effect of AZD6234 as an Adjunct to Incretin-based Therapies in Adult Participants With Obesity or Overweight With Weight-related Comorbidity With or Without Type 2 Diabetes Mellitus
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 9, 2026 · NCT07776509A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 9, 2026 · NCT07351058A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD1043 in Healthy Adult Participants Living With Overweight and/or Obesity.
Nagre-recruitPhase 1Malugod na tinatanggap ang malusog na boluntaryo
Edad 18 hanggang 65 · Lahat ng kasarian · Na-update Nob 9, 2026 · NCT07511205An Online Intuitive Eating Program for Pregnant Women With Obesity to Support Well-Being
Nagre-recruit
Edad 18 pataas · Kababaihan · Na-update Nob 6, 2026 · NCT07792837Scalable TELeheaLth Cancer CARe: The STELLAR Program to Treat Cancer Risk Behaviors
Nagre-recruit
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 6, 2026 · NCT05687604Study of Olatorepatide in Adult Participants Living With Overweight or Obesity Without Diabetes
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 6, 2026 · NCT07685808Metabolic Health, Bones and Nuts During Weight Loss in Adults
Nagre-recruitMalugod na tinatanggap ang malusog na boluntaryo
Edad 50 hanggang 75 · Lahat ng kasarian · Na-update Nob 6, 2026 · NCT06949280Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)
Nagre-recruitPhase 3
Edad 18 hanggang 99 · Lahat ng kasarian · Na-update Nob 6, 2026 · NCT07575399A Study to Learn How Different Forms of the Study Medicine Called Berobenatide is Taken up Into the Blood in Adults With Overweight or Obesity
Nagre-recruitPhase 1Malugod na tinatanggap ang malusog na boluntaryo
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 6, 2026 · NCT07876531A Study to Learn About the Monthly Dosing Study Medicine Called Berobenatide in Adults With Breathing Problems During Sleep and Overweight or Obesity Who Use a Breathing Machine (PAP) (VESPER-OSA 1)
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 5, 2026 · NCT07823608A Study to Learn About Switching to a Monthly Study Medicine Called Berobenatide (PF-08653944) to Help Keep Weight Off in People With Overweight or Obesity
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 5, 2026 · NCT07845500Maridebart Cafraglutide Versus Semaglutide in Participants With Type 2 Diabetes
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 5, 2026 · NCT07866066The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 5, 2026 · NCT05972564A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 5, 2026 · NCT07843498A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 5, 2026 · NCT07843485A Study to Learn About Study Medicine Called Berobenatide in Adults With Knee Pain and Overweight or Obesity (VESPER-OA 1)
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 5, 2026 · NCT07919678Mula sa ClinicalTrials.gov, na-kuha noong Nob 15, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.